ESR1 and breast carcinoma: The majority of breast cancer patients are however ER-positive, and the main focus therefore lies in identifying ER-positive patients with a risk of recurrence sufficiently low to avoid extensive adjuvant treatment, and at the same time identify high-risk patients within a low-risk cohort.